Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

BeyondSpring Inc. BYSI

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-1.0M
$-19.8M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -1.0
-40M-80M
20142017202020232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2022 · Operating -2756.4%
-10000%-20000%-30000%
201420192025
ROE
FY2021 · ROE -111.6%
-200%-400%
201420192025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -50%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -19.8
-20M-40M
201420192025

Total assetsUSD 25.9M
EquityUSD -32.2M
CashUSD 7.8M
Current ratio1.54×

Equity funds -124% of total assets.

The 12-year record

12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
BYSI, 12-year financial record
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.1−0.1−0.0−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.1−0.1−0.0−0.1−0.1−0.0−0.0−0.0
Income tax $B0.00.0−0.00.00.00.00.0◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.1−0.1−0.0−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0◌
EPS, diluted $◌◌◌◌−1.64−2.03−1.55−2.42−4.40−0.75−0.53−0.22
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————
ROE %————−111.6−102.8——−467.8−113.8——
Shares out B◌0.040.040.040.040.040.030.020.020.020.02◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures · 1 divergence in 43 reconciliationsAUDITED

Reconciled in 11 of the 12 fiscal years we could check. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 16 checks were skipped: the balance sheet is not tagged before 2015. Seven checks were skipped: EPS is not tagged before 2014.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures1 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2014

Share this section

Download image